News coverage about CTI BioPharma (NASDAQ:CTIC) has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CTI BioPharma earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.1282205491212 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
A number of research analysts recently commented on CTIC shares. Needham & Company LLC started coverage on shares of CTI BioPharma in a research note on Monday, March 26th. They issued a “buy” rating and a $10.00 price target on the stock. Cann reiterated a “buy” rating and issued a $5.00 price target on shares of CTI BioPharma in a research note on Wednesday, March 7th. Zacks Investment Research upgraded shares of CTI BioPharma from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research note on Wednesday, December 27th. JMP Securities started coverage on shares of CTI BioPharma in a research note on Wednesday, March 7th. They issued an “outperform” rating and a $8.00 price target on the stock. Finally, Oppenheimer started coverage on shares of CTI BioPharma in a research note on Friday, February 23rd. They issued an “outperform” rating and a $5.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $6.42.
Shares of NASDAQ:CTIC opened at $3.81 on Monday. CTI BioPharma has a 12-month low of $2.45 and a 12-month high of $4.52. The company has a market cap of $220.91, a price-to-earnings ratio of -3.07 and a beta of 0.14. The company has a current ratio of 2.44, a quick ratio of 2.41 and a debt-to-equity ratio of 0.90.
CTI BioPharma (NASDAQ:CTIC) last announced its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.04). CTI BioPharma had a negative return on equity of 233.13% and a negative net margin of 161.74%. The business had revenue of $0.46 million for the quarter, compared to analyst estimates of $1.00 million. During the same quarter in the previous year, the company earned ($0.70) EPS. equities analysts expect that CTI BioPharma will post -0.9 earnings per share for the current fiscal year.
In other CTI BioPharma news, insider Value Fund L. P. Biotechnology bought 6,333,333 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were purchased at an average price of $3.00 per share, for a total transaction of $18,999,999.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Bvf Partners L. P/Il bought 5,634,108 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were acquired at an average price of $3.00 per share, for a total transaction of $16,902,324.00. The disclosure for this purchase can be found here. Corporate insiders own 2.72% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/09/cti-biopharma-ctic-earning-somewhat-favorable-press-coverage-analysis-finds.html.
About CTI BioPharma
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.